CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.

SRT of CBE-treated animals resulted in an approximately 25% reduction in total GL-1 levels, although this did not reach statistical significance ( Figure 2a ).

also in 111,027 other papers